Latest news with #CIC
The South African
16 hours ago
- Politics
- The South African
Duduzile claps back at Floyd Shivambu's 'takes drugs' comments
Duduzile Zuma-Samudla has finally responded to shady comments made by fellow MK Party MP, Floyd Shivambu. In a press briefing on Thursday, 19 June, the former secretary general accused his party nemesis of 'taking drugs'. Floyd was effectively demoted after the party condemned his visit to the wanted Malawian preacher, Shepard Bushiri, last month. On her Instagram Story, Duduzile shared a clip of herself laughing with EFF President Julius Malema. Like Duduzile, Floyd Shivambu threw Malema under the bus, claiming the latter was running a 'cult.' The daughter of Jacob Zuma captioned the clip: 'It's politics after all'. Image via Instagram: @duduzilezuma_sambudla Like Duduzile, Julius Malema has also subtly responded to Floyd Shivambu's comments. After the press conference, the 'CIC' reacted to Floyd's criticism of the EFF and those who supported him. Malema posted a clip of EFF top brass on X: 'The leadership we have is quite alright.' During the briefing, Floyd addressed several topics, including an interest in possibly establishing his own political party. The former MK Party secretary-general also used the opportunity to making shady comments about the ANC, which he labelled as 'directionless' and the EFF, which he called a 'cult'. Referring to his own party, Floyd made a comment many believe was directed at Duduzile, the daughter of the MK Party founder, Jacob Zuma. He said, 'When you raise issues internally, you don't need to gossip about them anywhere. All the issues and concerns I had about MK, I raised internally, even against all odds. When there is an opportunity to raise an issue about wrongdoings. I clearly speak against untouchables who take drugs, tweet at night, and insult us.' He added: 'We confront them and say 'What is this about?'' Let us know by leaving a comment below, or send a WhatsApp to 060 011 021 1 . Subscribe to The South African website's newsletters and follow us on WhatsApp , Facebook , X, and Bluesky for the latest news.
Mint
4 days ago
- Business
- Mint
What is DPD in a credit report and why does it matter?
Credit cardholders and loan borrowers need to ensure the repayment is made before or by the due date. Timely payments help in maintaining and/or improving the credit score. A good credit score is important for getting new credit cards and loans. While processing new credit applications, banks look at the applicant's past repayment track record. It can be tracked through the Days Past Due (DPD) parameter in the credit report. In this article, we will understand what is DPD, various values reflected under DPD status in the credit report, and their implications. The Days Past Due or DPD status in a credit report reflects the number of days by which a credit cardholder or loan borrower has delayed a repayment. Banks report the repayment status for credit card outstanding and loan EMIs to Credit Information Companies (CICs) like CIBIL on a fortnightly basis as per RBI guidelines. The CICs like CIBIL process the information and update it in the individual's credit report. The credit report gives a month-wise repayment status of every credit instrument availed by the borrower. For example, suppose an individual holds a credit card from HDFC Bank. The credit report will reflect the monthly payment status for the card. The status is displayed month-wise for the last 36 months, starting from the latest month. Let us understand how the DPD status is reflected in the credit report and the meaning of each status. The month-wise DPD status in the credit report shows one of the following. DPD status 0: When the DPD status for any month is displayed as 0, it means the repayment has been made before or by the due date. You must always aim to make every repayment before or by the due date. When you do that, the bank reports the DPD status as 0 to the CIC, and the CIC further updates the same as 0 in your credit profile. When you make timely repayments month after month, you demonstrate a good repayment track record. The DPD status as 0 reflects good credit behaviour. When you apply for a new credit card or loan, the bank will check your credit report for the past payment track record. When they see a good payment track record, the chances of the credit application getting approved increase. Timely repayments have the highest weightage in the calculation of your credit score. Thus, when your DPD status is 0 with every passing month, it contributes towards improving your credit score. DPD status XXX: In some months, you will see the DPD status displayed as XXX. It means, the bank has not reported your repayment status for that particular month to the CIC. You don't have to worry about it, as it doesn't have any negative implication on your credit score. If your DPD status is anything other than 0 or XXX, you need to check further. Before we look into these statuses, let us understand how the DPD is calculated in the event of delayed repayment(s). Whenever a loan EMI or credit card outstanding is delayed beyond the due date, the DPD is calculated as follows. The DPD is the difference between the current date and the due date. For example, suppose the current date is 1st May 2025, and the loan EMI repayment date was 1st April 2025, and the EMI repayment is still pending. The DPD will be the number of days between the current date and the EMI repayment due date. In this case, the DPD will be 30 days. The bank will report the 30 days repayment delay to the CIC, and the CIC will update the DPD as 30 days in the borrower's credit report. Any repayment delay will impact your credit score negatively. Now, let us understand the DPD status for a delayed repayment. Depending on the duration for which a repayment has been delayed, the DPD status will be as follows. STD: The DPD status as STD or Standard means the repayment delay is less than 90 days. Every repayment delay impacts the credit score negatively. However, as the account is still standard, the impact may be less severe. The DPD status as STD or Standard means the repayment delay is less than 90 days. Every repayment delay impacts the credit score negatively. However, as the account is still standard, the impact may be less severe. SUB: The DPD status as SUB or Sub-standard means the repayment delay is more than 90 days. A credit account where the delay has crossed 90 days is classified as a non-performing asset (NPA) as per RBI guidelines. The DPD status as SUB or Sub-standard means the repayment delay is more than 90 days. A credit account where the delay has crossed 90 days is classified as a non-performing asset (NPA) as per RBI guidelines. DBT: The DPD status as DBT or Doubtful means it has remained a Sub-standard account for a period of 12 months. The probability of collection from a doubtful account is low. The DPD status as DBT or Doubtful means it has remained a Sub-standard account for a period of 12 months. The probability of collection from a doubtful account is low. LSS: The DPD status as LSS or Loss means a loss has been identified and remains uncollectible. When you apply for a new credit card or loan, the bank will check your credit score and profile. In the credit profile, they will check the DPD status of your existing/closed credit cards and loans. If the DPD status of all past repayments is either 0 or XXX, it will be viewed positively. The chances of the new credit application getting approved will increase. If the bank comes across any DPD status apart from 0 or XXX, it will check further details. A DPD status like STD, SUB, DBT, LSS, etc., can reduce the probability of the new credit application getting approved. You need a good credit score to improve the chances of your credit card or loan application getting approved. Some steps to increase and maintain a good credit score include the following. Timely repayments: Always pay the credit card outstanding and loan EMI before or by the due date. It will ensure the DPD status is 0. Always pay the credit card outstanding and loan EMI before or by the due date. It will ensure the DPD status is 0. Lower credit utilisation ratio: The credit utilisation ratio measures the percentage of credit used from the available credit limit. A credit utilisation ratio of 30% or lower is considered good. The credit utilisation ratio measures the percentage of credit used from the available credit limit. A credit utilisation ratio of 30% or lower is considered good. Healthy credit mix: An individual should have a healthy credit mix of secured loans (for example, home loan, vehicle loan, etc.) and unsecured loans (for example, credit card, personal loan, etc.) An individual should have a healthy credit mix of secured loans (for example, home loan, vehicle loan, etc.) and unsecured loans (for example, credit card, personal loan, etc.) Make one credit application at a time: An individual should make one credit application and wait for the bank to give its decision. Making multiple applications within a short period is considered credit-hungry behaviour by banks. An individual should check their credit report regularly. They should monitor the DPD status and other details. If the DPD status is anything other than 0 or XXX, it should be checked further. Always make timely payments so that the DPD status is 0. It helps in contributing towards increasing the credit score and maintaining it healthy. It also increases the chances of new credit applications getting approved. Gopal Gidwani is a freelance personal finance content writer with 15+ years of experience. He can be reached at LinkedIn.
South China Morning Post
6 days ago
- Business
- South China Morning Post
Home-grown construction innovations set for global rollout
[The content of this article has been produced by our advertising partner.] Hong Kong's Construction Industry Council (CIC) is set to transform local know-how into customisable and adaptable solutions when it stages the Construction Innovation Expo 2025 (CIExpo) from December 11 to 13 at the Hong Kong Convention and Exhibition Centre. CIC chairman Thomas Ho On-sing says CIExpo 2025 will showcase smart construction technologies and Hong Kong professionals' expertise in adapting them for projects at home and abroad. Four thematic zones of innovation According to CIC chairman Thomas Ho On-sing, the triennial event will showcase latest smart construction technologies as well as the ability of Hong Kong's building professionals and tech partners in integrating and tailoring them for construction projects at home and abroad. Building on the success of the 2022 edition, which drew over 21,000 visits, 173 exhibitors and more than 2,500 conference participants, CIExpo 2025 will be divided into four thematic zones: productivity, smart construction, sustainability and safety. In addition to the exhibition halls, the three-day event will host live demonstrations, immersive site tours and a robust line-up of international conferences covering: International Construction Leadership and New Quality Productive Forces (NQPF) Construction Safety Culture and Smart Site Safety System (4S) Modular Integrated Construction (MiC) / Multi-trade integrated MEP (MiMEP) Sustainable and Smart Construction practices Export-ready solutions
Yahoo
13-06-2025
- Business
- Yahoo
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates. Results showed that the CIC and flu vaccines generated 'robust immune responses' across three flu strains (H1N1, H3N2 and B) and the SARS-CoV-2 strain in adults aged 65 and older. Per Novavax, these responses were similar to those seen with its own approved COVID-19 vaccine, Nuvaxovid, and Sanofi's SNY influenza vaccine, Fluzone HD. Novavax emphasized that this study was not designed to demonstrate statistical significance but to provide preliminary immunogenicity data. It intends to use these findings to design another late-stage study, which could potentially support regulatory submissions, if successful. NVAX is also exploring strategic collaborations to finance further development and potential commercialization of both candidates. This is part of the company's recent strategic shift focused on expanding its pipeline and exploring partnership opportunities for the same. Shares of Novavax have underperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research The above announcement came just under a month after it received the long-awaited FDA approval for Nuvaxovid, albeit with a narrower label than initially expected. While the agency granted full approval to the vaccine for use in older adults aged 65 and above, it restricted the use in individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. This latest approval aligns with the FDA's recently issued guidance for COVID-19 vaccine boosters. As part of this guidance, COVID vaccine makers will be required to conduct randomized, placebo-controlled clinical studies demonstrating the real-world benefit of yearly COVID vaccine boosters in individuals aged under 65 years. Starting this year, Sanofi has acquired exclusive rights to market Nuvaxovid globally, except in certain territories where Novavax maintains existing partnership agreements. This arrangement is part of a multi-billion-dollar deal signed last year, wherein Sanofi assumed commercial responsibility for the vaccine. The company is also eligible for ongoing tiered royalties on future sales of COVID-19 vaccines. Apart from Novavax, Pfizer PFE and Moderna MRNA are also developing their respective COVID/flu combination vaccines using mRNA technology. Despite the recent regulatory setback, Moderna remains ahead of its competitors with the development of its investigational COVID-19/flu vaccine candidate, mRNA-1083. Moderna had to voluntarily withdraw its FDA filing for mRNA-1083 to accommodate the agency's request for additional efficacy data on the flu component of the vaccine. Moderna intends to resubmit the filing later this year. Pfizer suffered a major setback in this space last year when it reported data from a phase III study on its investigational mRNA-based COVID-19/flu combination vaccine. The study missed one of its two primary immunogenicity objectives. Pfizer is currently evaluating adjustments to its combination vaccine program to improve immune responses against influenza B and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech. Novavax's deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under this arrangement. Last year, the FDA granted fast-track designation to two of Sanofi's experimental combination vaccines, both being evaluated in separate phase I/II studies. While the first combination uses the Fluzone HD vaccine with Nuvaxovid, the second pairs Novavax's COVID-19 shot with Flubok. Novavax, Inc. price | Novavax, Inc. Quote Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report Novavax, Inc. (NVAX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Insider
12-06-2025
- Business
- Business Insider
Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses'
Novavax (NVAX) stock jumped on Wednesday after the vaccine maker released results from a Phase 3 clinical trial of its COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine. The initial cohort results from this study included 'robust immune responses' for the CIC and flu vaccine that were comparable to licensed rivals Nuvaxovid and Fluzone HD. Confident Investing Starts Here: Additionally, Novavax noted that the two vaccines were well tolerated. Almost all of the adverse events, greater than 98%, that were experienced by patients were mild or moderate in severity. The trial includes roughly 2,000 patients aged 65 or older. Novavax stated that it will continue to seek partners to further the development of its CIC and stand-alone flu vaccines. The results from this study provide it with the data it needs for discussions with potential partners. NVAX Stock Movement Today While NVAX stock had soared more than 2% in pre-market trading, the company couldn't maintain those gains. As a result, the stock is only up 0.56% as of Wednesday morning. Investors will also note that shares are down 8.83% year-to-date and 54.6% over the past 12 months. The Phase 3 clinical trial data also failed to attract investor interest today. Trading volume was muted at 1.38 million shares, compared to a three-month daily average of roughly 11.29 million units. Is Novavax Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Novavax is Hold, based on one Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NVAX stock price target of $11.25, representing a potential 55.39% upside for the shares. Spark, TipRanks' AI analyst, highlighted 'strong revenue growth and profitability improvements' but warned of 'negative equity and cash flow challenges.'
